CREBBP Antibody (N-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP1077a
Background:
CREBBP is an acetyltransferase enzyme that acetylates histones, giving a specific tag for transcriptional activation. It also acetylates non-histone proteins, like NCOA3 coactivator. This protein mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. CBP, as coactivator, augments the activity of phosphorylated CREB to activate transcription of cAMP-responsive genes. Chromosomal aberrations involving CREBBP may be a cause of acute myeloid leukemias. For example, MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription. Defects in CREBBP are also the cause of Rubinstein-Taybi syndrome (RSTS). RSTS is an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies.
Other Names:
CREB-binding protein, CREBBP, CBP
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1077a was selected from the N-term region of human CREBBP. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: CREBBP (HGNC:2348)
Gene ID: 1387
Primary Accession: Q92793
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
CREBBP is an acetyltransferase enzyme that acetylates histones, giving a specific tag for transcriptional activation. It also acetylates non-histone proteins, like NCOA3 coactivator. This protein mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. CBP, as coactivator, augments the activity of phosphorylated CREB to activate transcription of cAMP-responsive genes. Chromosomal aberrations involving CREBBP may be a cause of acute myeloid leukemias. For example, MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription. Defects in CREBBP are also the cause of Rubinstein-Taybi syndrome (RSTS). RSTS is an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies.
Other Names:
CREB-binding protein, CREBBP, CBP
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1077a was selected from the N-term region of human CREBBP. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: CREBBP (HGNC:2348)
Gene ID: 1387
Primary Accession: Q92793
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review